Listen to the latest hemonc news from international experts
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients with relapsed/refractory (R/R) disease. Several clinical trials are evaluating the efficacy of CAR-T cells and are further exploring the possibility of bringing these agents into earlier lines of therapy. At the 2023 EHA meeting, leading experts from around the globe came together to discuss the latest updates in all areas of hematological oncology.
In this podcast, you will hear from Jesús San Miguel, MD, University of Navarra, Pamplona, Spain, and Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, who share some updates from the CARTITUDE-4 and CARTITUDE-1 trials (NCT04181827; NCT03548207), and further comment on current and emerging uses of measurable residual disease (MRD) in clinical practice.
Date: 22nd June 2023